Investors sold shares of Merck & Company, Inc. (NYSE:MRK) on strength during trading hours on Tuesday. $82.08 million flowed into the stock on the tick-up and $219.93 million flowed out of the stock on the tick-down, for a money net flow of $137.85 million out of the stock. Of all equities tracked, Merck & had the 0th highest net out-flow for the day. Merck & traded up $0.17 for the day and closed at $54.27

A number of equities analysts have recently weighed in on MRK shares. BMO Capital Markets reissued a “buy” rating and set a $72.00 price target on shares of Merck & in a research report on Friday, September 8th. UBS Group AG lifted their price target on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a research report on Saturday, July 29th. Citigroup Inc. raised shares of Merck & from a “neutral” rating to a “buy” rating and set a $72.00 price target on the stock in a research report on Wednesday, October 18th. Finally, J P Morgan Chase & Co set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a research report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $66.87.

The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. The stock has a market cap of $147,855.20, a P/E ratio of 13.95, a PEG ratio of 2.34 and a beta of 0.78.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.07 EPS. equities analysts expect that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

In other news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.25% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in MRK. Janus Henderson Group PLC increased its stake in shares of Merck & by 172.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,705,564 shares of the company’s stock worth $429,347,000 after purchasing an additional 4,243,246 shares during the last quarter. Capital International Investors increased its stake in shares of Merck & by 55.3% during the 3rd quarter. Capital International Investors now owns 9,623,382 shares of the company’s stock worth $616,185,000 after purchasing an additional 3,428,400 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Merck & by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock worth $12,442,709,000 after purchasing an additional 3,312,459 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Merck & by 95,700.4% during the 3rd quarter. Stifel Financial Corp now owns 3,281,163 shares of the company’s stock worth $210,016,000 after purchasing an additional 3,277,738 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its stake in shares of Merck & by 415.5% during the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 3,560,465 shares of the company’s stock worth $227,977,000 after purchasing an additional 2,869,844 shares during the last quarter. Institutional investors own 72.98% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/traders-sell-merck-company-inc-mrk-on-strength-mrk/1721477.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.